Search

Your search keyword '"Vtorushin, Sergey"' showing total 33 results
Start Over Author "Vtorushin, Sergey" Search Limiters Full Text

Refine your results

more »

more »

more »
33 results on '"Vtorushin, Sergey"'

6. The Composition of Small Extracellular Vesicles (sEVs) in the Blood Plasma of Colorectal Cancer Patients Reflects the Presence of Metabolic Syndrome and Correlates with Angiogenesis and the Effectiveness of Thermoradiation Therapy

Author

Yunusova, Natalia V., primary, Svarovsky, Dmitry A., additional, Konovalov, Artem I., additional, Kostromitsky, Dmitry N., additional, Startseva, Zhanna A., additional, Cheremisina, Olga V., additional, Afanas’ev, Sergey G., additional, Kondakova, Irina V., additional, Grigor’eva, Alina E., additional, Vtorushin, Sergey V., additional, Sereda, Elena E., additional, Usova, Anna V., additional, and Tamkovich, Svetlana N., additional

Published
2023
Full Text
View/download PDF

7. Phase I Trial of [Tc-99m]Tc-maSSS-PEG(2)-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors

Author

Chernov, Vladimir, Rybina, Anastasiya, Zelchan, Roman, Medvedeva, Anna, Bragina, Olga, Lushnikova, Nadejda, Doroshenko, Artem, Usynin, Evgeniy, Tashireva, Liubov, Vtorushin, Sergey, Abouzayed, Ayman, Rinne, Sara S., Sörensen, Jens, Tolmachev, Vladimir, Orlova, Anna, Chernov, Vladimir, Rybina, Anastasiya, Zelchan, Roman, Medvedeva, Anna, Bragina, Olga, Lushnikova, Nadejda, Doroshenko, Artem, Usynin, Evgeniy, Tashireva, Liubov, Vtorushin, Sergey, Abouzayed, Ayman, Rinne, Sara S., Sörensen, Jens, Tolmachev, Vladimir, and Orlova, Anna

Abstract

The gastrin-releasing peptide receptor (GRPR) is overexpressed in prostate cancer (PCa) and in hormone-driven breast cancer (BCa). The aim of this phase I clinical trial was to evaluate safety, biodistribution, and dosimetry after the administration of the recently developed GRPR-targeting antagonistic bombesin analogue [Tc-99m]Tc-maSSS-PEG(2)-RM26 in PCa and BCa patients. Planar and whole-body SPECT/CT imaging was performed in six PCa patients and seven BCa patients 2, 4, 6, and 24 h post the intravenous administration of 40 mu g of [Tc-99m]Tc-maSSS-PEG(2)-RM26 (600-700 MBq). No adverse events or pathological changes were observed. The rapid blood clearance of [Tc-99m]Tc-maSSS-PEG(2)-RM26 was observed with predominantly hepatobiliary excretion. The effective doses were 0.0053 +/- 0.0007 for male patients and 0.008 +/- 0.003 mSv/MBq for female patients. The accumulation of [Tc-99m]Tc-maSSS-PEG(2)-RM26 in tumors was observed in four out of six PCa and in seven out of seven BCa patients. In four BCa patients, a high uptake of the agent into the axillary lymph nodes was detected. Immunohistochemistry revealed positive GRPR expression in 60% of primary PCa, 71.4% of BCa tumors, and 50% of examined BCa lymph nodes. In conclusion, a single administration of [Tc-99m]Tc-maSSS-PEG(2)-RM26 was safe and well tolerated. [Tc-99m]Tc-maSSS-PEG(2)-RM26 SPECT may be useful for tumor detection in PCa and BCa patients, pending further studies.

Published
2023
Full Text
View/download PDF

8. Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors

Author

Chernov, Vladimir, primary, Rybina, Anastasiya, additional, Zelchan, Roman, additional, Medvedeva, Anna, additional, Bragina, Olga, additional, Lushnikova, Nadejda, additional, Doroshenko, Artem, additional, Usynin, Evgeniy, additional, Tashireva, Liubov, additional, Vtorushin, Sergey, additional, Abouzayed, Ayman, additional, Rinne, Sara S., additional, Sörensen, Jens, additional, Tolmachev, Vladimir, additional, and Orlova, Anna, additional

Published
2023
Full Text
View/download PDF

12. Experimental Simulation of Compression Anastomosis in Double-Barreled Enterostomy Using a Titanium Nickelide Memory Shape Device

Author

Ivanov, Stanislav Dmitrievich, primary, Slizovskiу, Grigoriу Vladimirovich, additional, Shikunova, Yana Vladimirovna, additional, Vtorushin, Sergey Vladimirovich, additional, Vasilchenko, Dmitrii Vladimirovich, additional, Gunther, Viktor Eduardovich, additional, Khodorenko, Valentina Nikolaevna, additional, and Anikeev, Sergei Gennadievich, additional

Published
2022
Full Text
View/download PDF

13. Phase I Trial of [ 99m Tc]Tc-maSSS-PEG 2 -RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors.

Author

Chernov, Vladimir, Rybina, Anastasiya, Zelchan, Roman, Medvedeva, Anna, Bragina, Olga, Lushnikova, Nadejda, Doroshenko, Artem, Usynin, Evgeniy, Tashireva, Liubov, Vtorushin, Sergey, Abouzayed, Ayman, Rinne, Sara S., Sörensen, Jens, Tolmachev, Vladimir, and Orlova, Anna

Subjects
BREAST tumor diagnosis, TUMOR treatment, TUMOR diagnosis, CLINICAL trials, ACADEMIC medical centers, NEUROPEPTIDES, IMMUNOHISTOCHEMISTRY, CELL receptors, LYMPH nodes, CONTRAST media, TREATMENT effectiveness, CANCER patients, SINGLE-photon emission computed tomography, RESEARCH funding, DESCRIPTIVE statistics, PEPTIDE hormones, COMPUTED tomography, TECHNETIUM compounds, PROSTATE tumors, RADIATION dosimetry, CHEMICAL inhibitors
Abstract

Simple Summary: Prostate and breast cancers are the most common malignancies. Accurate diagnosis and staging of diseases are important for the prognosis and determination of treatment tactics. The gastrin-releasing peptide receptor is overexpressed in over 80% of estrogen receptor-positive breast cancers and in up to 100% of primary prostate cancers, particularly in prostate cancers of lower grades and smaller sizes. Our group has developed an imaging agent [99mTc]Tc-maSSS-PEG2-RM26 suitable for the detection of gastrin-releasing peptide receptors' expression using SPECT. We aimed to perform a first-in-human study to test the safety of [99mTc]Tc-maSSS-PEG2-RM26 administration, to study its biological distribution in normal organs, and to evaluate the agent's targeting of receptors in tumors. This phase I study was performed in six prostate and seven breast cancer patients. Single injections of the new agent were well tolerated and a number of prostate and breast cancer primary tumors as well as metastases were visualized with SPECT/CT shortly after administration. The gastrin-releasing peptide receptor (GRPR) is overexpressed in prostate cancer (PCa) and in hormone-driven breast cancer (BCa). The aim of this phase I clinical trial was to evaluate safety, biodistribution, and dosimetry after the administration of the recently developed GRPR-targeting antagonistic bombesin analogue [99mTc]Tc-maSSS-PEG2-RM26 in PCa and BCa patients. Planar and whole-body SPECT/CT imaging was performed in six PCa patients and seven BCa patients 2, 4, 6, and 24 h post the intravenous administration of 40 µg of [99mTc]Tc-maSSS-PEG2-RM26 (600–700 MBq). No adverse events or pathological changes were observed. The rapid blood clearance of [99mTc]Tc-maSSS-PEG2-RM26 was observed with predominantly hepatobiliary excretion. The effective doses were 0.0053 ± 0.0007 for male patients and 0.008 ± 0.003 mSv/MBq for female patients. The accumulation of [99mTc]Tc-maSSS-PEG2-RM26 in tumors was observed in four out of six PCa and in seven out of seven BCa patients. In four BCa patients, a high uptake of the agent into the axillary lymph nodes was detected. Immunohistochemistry revealed positive GRPR expression in 60% of primary PCa, 71.4% of BCa tumors, and 50% of examined BCa lymph nodes. In conclusion, a single administration of [99mTc]Tc-maSSS-PEG2-RM26 was safe and well tolerated. [99mTc]Tc-maSSS-PEG2-RM26 SPECT may be useful for tumor detection in PCa and BCa patients, pending further studies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy

Author

Yin, Wen, primary, Xu, Tianqi, additional, Altai, Mohamed, additional, Oroujeni, Maryam, additional, Zhang, Jie, additional, Vorobyeva, Anzhelika, additional, Vorontsova, Olga, additional, Vtorushin, Sergey V., additional, Tolmachev, Vladimir, additional, Gräslund, Torbjörn, additional, and Orlova, Anna, additional

Published
2021
Full Text
View/download PDF

15. Premalignant Changes in the Bronchial Epithelium Are Prognostic Factors of Distant Metastasis in Non-Small Cell Lung Cancer Patients

Author

Pankova, Olga V., primary, Tashireva, Liubov A., additional, Rodionov, Evgeny O., additional, Miller, Sergey V., additional, Tuzikov, Sergey A., additional, Pismenny, Dmitry S., additional, Gerashchenko, Tatiana S., additional, Zavyalova, Marina V., additional, Vtorushin, Sergey V., additional, Denisov, Evgeny V., additional, and Perelmuter, Vladimir M., additional

Published
2021
Full Text
View/download PDF

16. The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy

Author

Yin, Wen, Xu, Tianqi, Altai, Mohamed, Oroujeni, Maryam, Zhang, Jie, Vorobyeva, Anzhelika, Vorontsova, Olga, Vtorushin, Sergey V., Tolmachev, Vladimir, Graslund, Torbjorn, Orlova, Anna, Yin, Wen, Xu, Tianqi, Altai, Mohamed, Oroujeni, Maryam, Zhang, Jie, Vorobyeva, Anzhelika, Vorontsova, Olga, Vtorushin, Sergey V., Tolmachev, Vladimir, Graslund, Torbjorn, and Orlova, Anna

Abstract

Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the influence of the number and positioning of the protein domains in the drug conjugate. Seven HER2-targeting affibody-based constructs, including one or two affibody molecules (Z) with or without an albumin-binding domain (ABD), namely Z, Z-ABD, ABD-Z, Z-Z, Z-Z-ABD, Z-ABD-Z, and ABD-Z-Z, were evaluated on their effects on cell growth, in vivo targeting, and biodistribution. The biodistribution study demonstrated that the monomeric constructs had longer blood retention and lower hepatic uptake than the dimeric ones. A dimeric construct, specifically ABD-Z-Z, could stimulate the proliferation of HER2 expressing SKOV-3 cells in vitro and the growth of tumors in vivo, whereas the monomeric construct Z-ABD could not. These two constructs demonstrated a therapeutic effect when coupled to mcDM1; however, the effect was more pronounced for the non-stimulating Z-ABD. The median survival of the mice treated with Z-ABD-mcDM1 was 63 days compared to the 37 days for those treated with ABD-Z-Z-mcDM1 or for the control animals. Domain permutation of an ABD-fused HER2-targeting affibody-based drug conjugate significantly influences tumor cell proliferation and therapy efficacy. The monomeric conjugate Z-ABD is the most promising format for targeted delivery of the cytotoxic drug DM1.

Published
2021
Full Text
View/download PDF

17. Sensitivity improvement techniques for micromechanical vibrating accelerometers

Author

Vtorushin Sergey and Nesterenko Tamara

Subjects
Engineering (General). Civil engineering (General), TA1-2040
Abstract

The paper presents the problems of detecting a desired signal generated by micromechanical vibrating accelerometer. Three detection methods, namely frequency, amplitude and phase are considered in this paper. These methods are used in micromechanical vibrating accelerometers that incorporate a force sensitive element which transforms measured acceleration into the output signal. Investigations are carried out using the ANSYS finite element program and MATLAB/Simulink support package. Investigation results include the comparative analysis of the output signal characteristics obtained by the different detection methods.

Published
2016
Full Text
View/download PDF

21. Clinically relevant morphological structures in breast cancer represent transcriptionally distinct tumor cell populations with varied degrees of epithelial-mesenchymal transition and CD44+CD24- stemness

Author

Denisov, Evgeny V., primary, Skryabin, Nikolay A., additional, Gerashchenko, Tatiana S., additional, Tashireva, Lubov A., additional, Wilhelm, Jochen, additional, Buldakov, Mikhail A., additional, Sleptcov, Aleksei A., additional, Lebedev, Igor N., additional, Vtorushin, Sergey V., additional, Zavyalova, Marina V., additional, Cherdyntseva, Nadezhda V., additional, and Perelmuter, Vladimir M., additional

Published
2017
Full Text
View/download PDF

24. Additional file 1: of Hemozoin 'knobs' in Opisthorchis felineus infected liver

Author

Pershina, Alexandra, Saltykova, Irina, Ivanov, Vladimir, Perina, Ekaterina, Demin, Alexander, Shevelev, Oleg, Buzueva, Irina, Gutakovskii, Anton, Vtorushin, Sergey, Ganebnykh, Ilya, Krasnov, Victor, Sazonov, Alexey, and Ogorodova, Ludmila

Subjects
parasitic diseases
Abstract

Hemozoin “knobs” in Opisthorchis felineus infected liver. Figure S1. Histological analysis of the liver of uninfected hamster (control). Macrophotograph of the liver of uninfected hamster (control) at (a) 5, (b) 24 and (c) 48 weeks after the start of the experiment. Histological analysis of the liver of uninfected hamster (control) at (d) 5, (e) 24 and (f) 48 weeks after the start of the experiment, hematoxylin and eosin staining (×200). Figure S2. UV-visible spectra of hemozoin (in water) extracted from Opisthorchis felineus (1) and the same amount of hemozoin dissolved in NaOH, SDS, EDTA buffer. Figure S3. The intensity profile of the designated area in Fig. 2e in article. Figure S4. The histogram of hemozoin crystals length in Opisthorchis felineus gut (PDF 529 kb)

Published
2015
Full Text
View/download PDF

25. CD68 expression in inflammatory cell infiltration of nonspecific invasive breast cancer

Author

Zavyalova, Marina V., Krakhmal, N. V., Telegina, Nadezhda, Vtorushin, Sergey V., Cherdyntseva, Nadezhda V., Kzhyshkowska, Julia, and Buldakov, Mikhail A.

Subjects
воспалительная клеточная инфильтрация, инвазивный рак молочной железы неспецифического типа, CD68
Published
2015

27. The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen

Author

Babyshkina, Nataliya, primary, Vtorushin, Sergey, additional, Zavyalova, Marina, additional, Patalyak, Stanislav, additional, Dronova, Tatyana, additional, Litviakov, Nikolay, additional, Slonimskaya, Elena, additional, Kzhyshkowska, Julia, additional, Cherdyntseva, Nadejda, additional, and Choynzonov, Evgeny, additional

Published
2016
Full Text
View/download PDF

29. Hemozoin “knobs” in Opisthorchis felineus infected liver

Author

Pershina, Alexandra G., primary, Saltykova, Irina V., additional, Ivanov, Vladimir V., additional, Perina, Ekaterina A., additional, Demin, Alexander M., additional, Shevelev, Oleg B., additional, Buzueva, Irina I., additional, Gutakovskii, Anton K., additional, Vtorushin, Sergey V., additional, Ganebnykh, Ilya N., additional, Krasnov, Victor P., additional, Sazonov, Alexey E., additional, and Ogorodova, Ludmila M., additional

Published
2015
Full Text
View/download PDF

31. Intratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expression

Author

Denisov, Evgeny V., primary, Litviakov, Nikolay V., additional, Zavyalova, Marina V., additional, Perelmuter, Vladimir M., additional, Vtorushin, Sergey V., additional, Tsyganov, Matvey M., additional, Gerashchenko, Tatiana S., additional, Garbukov, Evgeny Yu., additional, Slonimskaya, Elena M., additional, and Cherdyntseva, Nadezhda V., additional

Published
2014
Full Text
View/download PDF

32. Phenotypic Drift as a Cause for Intratumoral Morphological Heterogeneity of Invasive Ductal Breast Carcinoma Not Otherwise Specified

Author

Zavyalova, Marina V., primary, Denisov, Evgeny V., additional, Tashireva, Lubov A., additional, Gerashchenko, Tatiana S., additional, Litviakov, Nikolay V., additional, Skryabin, Nikolay A., additional, Vtorushin, Sergey V., additional, Telegina, Nadezhda S., additional, Slonimskaya, Elena M., additional, Cherdyntseva, Nadezhda V., additional, and Perelmuter, Vladimir M., additional

Published
2013
Full Text
View/download PDF

33. Clinically relevant morphological structures in breast cancer represent transcriptionally distinct tumor cell populations with varied degrees of epithelial-mesenchymal transition and CD44 + CD24 - stemness.

Author

Denisov EV, Skryabin NA, Gerashchenko TS, Tashireva LA, Wilhelm J, Buldakov MA, Sleptcov AA, Lebedev IN, Vtorushin SV, Zavyalova MV, Cherdyntseva NV, and Perelmuter VM

Abstract

Intratumor morphological heterogeneity in breast cancer is represented by different morphological structures (tubular, alveolar, solid, trabecular, and discrete) and contributes to poor prognosis; however, the mechanisms involved remain unclear. In this study, we performed 3D imaging, laser microdissection-assisted array comparative genomic hybridization and gene expression microarray analysis of different morphological structures and examined their association with the standard immunohistochemistry scorings and CD44 + CD24 - cancer stem cells. We found that the intratumor morphological heterogeneity is not associated with chromosomal aberrations. By contrast, morphological structures were characterized by specific gene expression profiles and signaling pathways and significantly differed in progesterone receptor and Ki-67 expression. Most importantly, we observed significant differences between structures in the number of expressed genes of the epithelial and mesenchymal phenotypes and the association with cancer invasion pathways. Tubular (tube-shaped) and alveolar (spheroid-shaped) structures were transcriptionally similar and demonstrated co-expression of epithelial and mesenchymal markers. Solid (large shapeless) structures retained epithelial features but demonstrated an increase in mesenchymal traits and collective cell migration hallmarks. Mesenchymal genes and cancer invasion pathways, as well as Ki-67 expression, were enriched in trabecular (one/two rows of tumor cells) and discrete groups (single cells and/or arrangements of 2-5 cells). Surprisingly, the number of CD44 + CD24 - cells was found to be the lowest in discrete groups and the highest in alveolar and solid structures. Overall, our findings indicate the association of intratumor morphological heterogeneity in breast cancer with the epithelial-mesenchymal transition and CD44 + CD24 - stemness and the appeal of this heterogeneity as a model for the study of cancer invasion., Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results